| IDXX | 8-K | bullish | 7/10 | IDEXX reported Q2 2026 EPS of $4.27, an 8.5% beat vs consensus of $3.93, on revenue of $1.217B (in line with $1.20B cons | Aug 4, 2026 |
| MRK | 8-K | neutral | 5/10 | Merck reported Q2 2026 revenue of $16.6B (+5% YoY), beating consensus of $16.37B, and non-GAAP EPS of -$0.13 vs consensu | Aug 4, 2026 |
| TLSA | 6-K | bullish | 5/10 | CEO Ivor Elrifi purchased 667,000 TLSA common shares at $1.00 per share on the open market, increasing his total holding | Aug 4, 2026 |
| ATTO | S-1/A | neutral | 6/10 | Attovia Therapeutics filed Amendment No. 2 to its S-1 for an IPO of 17,000,000 shares at an estimated $17.00 per share, | Aug 4, 2026 |
| ETON | 8-K | neutral | 2/10 | Eton Pharmaceuticals appointed Danka Radosavljevic, age 42, as Chief Operating Officer, effective July 31, 2026. She was | Aug 4, 2026 |
| BNTX | 6-K | bearish | 6/10 | BioNTech reported Q2 2026 revenues of €105.6M, down 60% YoY from €260.8M, driven by declining COVID-19 vaccine demand. T | Aug 4, 2026 |
| TOVX | 8-K | bearish | 4/10 | Theriva Biologics held its 2026 Annual Meeting on August 3, 2026, where stockholders approved all six proposals, includi | Aug 4, 2026 |
| NXTC | 425 | neutral | 5/10 | NextCure filed a 425 communication on August 4, 2026, publishing an Avere Therapeutics corporate presentation to potenti | Aug 4, 2026 |
| ZEOX | 8-K | neutral | 2/10 | Zeo ScientifiX announced the launch of ZEO Xperience, a three-day immersive educational conference for healthcare profes | Aug 4, 2026 |
| GALT | 8-K | mixed | 7/10 | Galectin Therapeutics (GALT) announced that Chairman Richard Uihlein converted $105.8 million in outstanding convertible | Aug 4, 2026 |
| CRVO | 8-K | bullish | 6/10 | CervoMed announced that its lead drug candidate, neflamapimod, has been granted an Innovation Passport under the UK's In | Aug 4, 2026 |
| RANI | 8-K | neutral | 2/10 | Rani Therapeutics appointed Michelle Gilson to its Board of Directors and as chair of the Audit Committee, effective Aug | Aug 4, 2026 |
| HRMY | 8-K | bullish | 7/10 | Harmony Biosciences reported record Q2 2026 WAKIX net revenue of $261.3M (+30% YoY), with GAAP diluted EPS of $1.28 beat | Aug 4, 2026 |
| JNJ | 8-K | neutral | 2/10 | Johnson & Johnson announced the retirement of Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, effec | Aug 4, 2026 |
| INCR | 6-K | neutral | 5/10 | No summary provided | Aug 4, 2026 |
| NVCT | 8-K | bullish | 7/10 | Nuvectis Pharma reported Q2 2026 results highlighting a transformative in-licensing of ciprocopan (NXP100) and NXP200 fr | Aug 4, 2026 |
| LSTA | 8-K | bearish | 7/10 | Lisata Therapeutics slashed ~72% of its workforce, terminated its CMO, and disclosed a lawsuit against merger counterpar | Aug 4, 2026 |
| EOLS | 8-K | neutral | 4/10 | Evolus expanded its partnership with Symatese to exclusively commercialize the Estyme injectable HA gel portfolio in Can | Aug 4, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.7 | Aug 4, 2026 |
| HRMY | PRESS-RELEASE | bullish | 6/10 | Harmony Biosciences reported Q2 2026 WAKIX net revenue of $261.3M, up 30% YoY and above $253.3M consensus, with diluted | Aug 4, 2026 |
| LPCN | PRESS-RELEASE | neutral | 5/10 | No summary provided | Aug 4, 2026 |
| WLKP | 8-K | neutral | 4/10 | Westlake Chemical Partners LP reported Q2 2026 EPS of $0.40, a 2.4% miss vs the $0.41 consensus, while net income attrib | Aug 4, 2026 |
| PVLA | 8-K | neutral | 5/10 | Palvella Therapeutics reported Q2 2026 results with a net loss of $1.52 per share, missing the consensus estimate of $-1 | Aug 4, 2026 |
| WLK | 8-K | bullish | 6/10 | Westlake Corp reported Q2 2026 results with a significant turnaround: net income of $260M ($2.01 EPS) vs a net loss of $ | Aug 4, 2026 |
| IBRX | 8-K | neutral | 5/10 | ImmunityBio reported record Q2 2026 net product revenue of $50.7M, up 92% YoY and 15% sequentially, marking the eighth c | Aug 4, 2026 |
| FTH | 8-K | neutral | 3/10 | Faeth Therapeutics (FTH) reported Q2 2026 financial results with a net loss of $16.0M ($2.84/share), compared to a net l | Aug 4, 2026 |
| RYTM | 8-K | bullish | 7/10 | Rhythm Pharmaceuticals reported Q2 2026 revenue of $71.3M (vs $67.7M consensus, +5.3% beat) and a GAAP EPS loss of -$0.7 | Aug 4, 2026 |
| ODTX | 8-K | neutral | 4/10 | Odyssey Therapeutics reported Q2 2026 financial results with a GAAP net loss of $52.8M, wider than the $41.2M loss in Q2 | Aug 4, 2026 |
| GRTX | 8-K | bearish | 8/10 | Galera Therapeutics completed its merger with Obsidian Therapeutics (formerly Gazelle Parent) on August 3, 2026, becomin | Aug 4, 2026 |
| LNTH | 8-K, DEFA14A | bullish | 8/10 | Lantheus (LNTH) has entered into a definitive merger agreement with Curium US Holdings LLC, a private equity-backed radi | Aug 4, 2026 |
